Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/177)
Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system (Class 514/178)
  • PHARMACEUTICAL VEHICLE
    Publication number: 20080274986
    Abstract: A pharmaceutical solution is capable of being ejected from a thermal fluid ejection device onto a substrate. The solution includes a vehicle with predetermined properties, and an active pharmaceutical ingredient with a solubility of at least about 30 mg/ml in the vehicle. The vehicle substantially evaporates from the substrate.
    Type: Application
    Filed: July 16, 2008
    Publication date: November 6, 2008
    Inventor: Vanessa I. Chinea
  • Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions
    Publication number: 20080269178
    Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.
    Type: Application
    Filed: November 16, 2005
    Publication date: October 30, 2008
    Inventors: John Miller, Paul Ronald, Adrian Ashley, Paul Lamb, Donald MacDonald, Martin Oliver, Matthew Pollard
  • Transdermal Delivery System for Treating Infertility
    Publication number: 20080255034
    Abstract: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises a drug (5a), wherein the drug effects at least one of the biological regulation of at least one oocyte containing follicle, stimulation of follicle growth, induction of ovulation, promotion of gestational status, maintenance of conceptus, maintenance of pregnancy.
    Type: Application
    Filed: October 6, 2006
    Publication date: October 16, 2008
    Applicant: PANTEC BIOSOLUTIONS AG
    Inventors: Christof Bohler, Thomas Bragagna, Reinhard Braun, Werner Braun, Herbert Zech
  • Steroid-Derived Pharmaceutical Compositions
    Publication number: 20080255076
    Abstract: The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.
    Type: Application
    Filed: June 29, 2005
    Publication date: October 16, 2008
    Applicants: JadoLabs GmbH, Max-Planck-Gesellschaft zur Forderung der Wissenschaftenhaften e.V., Technische Universitat Dresden
    Inventors: Tobias Braxmeier, Kai Simons, Marino Zerial, Teymuras Kurzchalia, Tim Friedrichson, Wolfgang Frohner, Gary Jennings, Georg Schlechtingen, Cornelia Schroeder, Hans-Joachim Knolker
  • Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
    Patent number: 7429576
    Abstract: Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3?, 17?-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: September 30, 2008
    Assignee: Endorecherche, Inc.
    Inventor: Fernand Labrie
  • METHOD OF TREATING AMYLOIDOSIS MEDIATED DISEASES
    Publication number: 20080234243
    Abstract: The compounds of the present invention can be used to inhibit formation of beta-amyloid protein. The present invention provides methods of preventing, delaying onset of, or treating diseases or conditions characterized or mediated by amyloidosis. In particular, the present invention is useful for preventing, delaying onset of, and treating Alzheimer's disease and related diseases causing dementia.
    Type: Application
    Filed: January 31, 2008
    Publication date: September 25, 2008
    Inventors: Theresa M. LaVallee, Anthony M. Treston, Todd A. Hembrough
  • Topical hormonal composition with systemic action
    Publication number: 20080227763
    Abstract: The present invention relates to the area of chemotherapy and more especially to the development of new galenic forms for application to the skin. It relates more particularly to a topical hormonal composition with systemic action for the correction of progesterone deficiency in premenopausal women and for hormone replacement in menopausal women, characterized in that it contains, as the active principle, a progestogen derived from 19-nor progesterone, a vehicle permitting systemic passage of the said active principle chosen from the group comprising a solubilizing agent, an absorption promoter, a film-forming agent, a gelling agent or their mixtures, combined with or mixed with suitable excipients for production of a pharmaceutical form as a gel and/or a film.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 18, 2008
    Inventors: Michel Lanquetin, Jacques Paris, Jean-Louis Thomas
  • Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
    Patent number: 7419971
    Abstract: Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17?-alkoxy-11?-hydroxyandrost-4-en-3-one-17?-carboxylate type and the corresponding ?1,4 compounds and of anti-inflammatory steroids of the hydrocortisone and prednisolone type are described. The enhancing agents have the formula: wherein R is H or C1-C4 alkyl; Z1 is carbonyl or ?-hydroxymethylene; X1 is —O— or —S—; R5 is —OH, —OR6, —OCOOR6 or —OCOR7 wherein R6 is C1-C4 alkyl and R7 is C1-C4 alkyl, fluoromethyl or chloromethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated; with the proviso that when R is C1-C4 alkyl, then R5 is —OH.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: September 2, 2008
    Inventor: Nicholas S. Bodor
  • Soft Gelatin Capsules
    Publication number: 20080206323
    Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.
    Type: Application
    Filed: March 13, 2006
    Publication date: August 28, 2008
    Inventors: Giorgio Zoppetti, Maurizio Marchiorri
  • Sustained Release Compositions Containing Progesterone Receptor Modulators
    Publication number: 20080199511
    Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.
    Type: Application
    Filed: July 8, 2005
    Publication date: August 21, 2008
    Applicant: Laboratoire HRA Pharma
    Inventors: Regine Sitruk-Ware, Yun-Yen Tsong
  • TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE
    Publication number: 20080194468
    Abstract: Methods and compositions for enhancing the activity and/or duration of action of loteprednol etabonate and other soft anti-inflammatory steroids of the haloalkyl 17?-alkoxycarbonyloxy-11?-hydroxyandrost-4-cn-3-one-17?-carboxylate type and the corresponding ?1,4-compounds are described. The enhancing agents have the formula: wherein Z1 is carbonyl, ?-hydroxymethylene or methylene; R2 is H, —OH or —OCOR3 wherein R3 is C1-5 alkyl; Y is —OH, —SH or —OCOR4 wherein R4 is C1-5 alkyl, cyclopentylethyl or diethylaminoethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated. Ophthalmic administration in the treatment of dry eye is specifically targeted.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 14, 2008
    Inventor: Nicholas S. Bodor
  • Dosage Form Comprising Therapeutic Formulation
    Publication number: 20080181944
    Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.
    Type: Application
    Filed: April 2, 2008
    Publication date: July 31, 2008
    Applicant: ALZA CORPORATION
    Inventors: Liang-Chang Dong, Patrick S.L. Wong, Vincent Joseph Ferrari, Steven Espinal
  • Androstane 17-Alpha Carbonate Derivatives for Use in the Treatment of Allergic and Inflammatory Conditions
    Publication number: 20080182831
    Abstract: The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydrogen, a methyl group, which may be in either the ? or ? configuration, or a methylene group; R3 and R4 are the same or a different group and each independently represents hydrogen, halogen or a methyl group; represents a single or a double bond; and physiologically acceptable solvates thereof, physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
    Type: Application
    Filed: January 9, 2006
    Publication date: July 31, 2008
    Inventors: Keith Biggadike, Deborah Needham
  • ESTROGEN/SERM AND ESTROGEN/PROGESTIN BI-LAYER TABLETS
    Publication number: 20080175905
    Abstract: The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation.
    Type: Application
    Filed: November 28, 2007
    Publication date: July 24, 2008
    Applicant: Wyeth
    Inventors: Xiuying Liu, John Kresevic, Nizamuddin Baksh, Robin Enever
  • Androstane 17-beta-carboxamides as androgen receptor modulators
    Patent number: 7402577
    Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 22, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman
  • TOPICAL ADMINISTRATION OF DANAZOL
    Publication number: 20080153789
    Abstract: Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty tissue, in particular in cases of cellulite, are disclosed herein. In a preferred embodiment, the drug is danazol or gastrinone. In another embodiment, the drug is danazol in combination with an aromatase inhibitor or an estrogen compound. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion, ointment, gel or emulsion, solution or foam.
    Type: Application
    Filed: December 26, 2007
    Publication date: June 26, 2008
    Inventors: Paul Dmowski, Gerianne T. DiPiano
  • Regional delivery of therapeutic agents for the treatment of vascular diseases
    Publication number: 20080146489
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Application
    Filed: December 15, 2006
    Publication date: June 19, 2008
    Inventors: Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F.A. Hossainy, Rachel Bright, Jeffrey Ellis
  • Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2
    Publication number: 20080139520
    Abstract: Disclosed herein are methods for regulation of fat and/or cholesterol uptake from the gastrointestinal tract and/or regulation of plasma fat and/or cholesterol levels comprising administering to a mammal in need thereof an effective amount of a regulator of pancreatic IB PLA2 functionality. Also disclosed herein are methods of regulating the function of a polypeptide of interest comprising inserting of the 62-66 loop region of a pancreatic IB PLA2 amino acid sequence into the polypeptide of interest; and administering an effective amount of a regulatory molecule that effects its regulation through said amino acid sequence. Further disclosed are novel bile salt compounds that regulate pancreatic IB PLA2. Methods for detecting altered pancreatic IB PLA2 function and methods for identifying an agent suitable for regulating pancreatic IB PLA2 enzyme functionality are also disclosed.
    Type: Application
    Filed: August 21, 2007
    Publication date: June 12, 2008
    Inventors: Mahendra K. Jain, Rafael J. Apitz-Castro, Otto G. Berg
  • Treatment for dry eye
    Publication number: 20080132475
    Abstract: The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 5, 2008
    Inventors: Charles Gerald Connor, Charles L. Haine
  • Certain lithocholic acid analogues that inhibit sialyltransferase
    Publication number: 20080119443
    Abstract: Certain chemical entities chosen from compounds of Formula I: and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof are described. Pharmaceutical compositions comprising at least one chemical entity chosen from compounds of Formula I and a pharmaceutically acceptable vehicle are described. Also described are methods for inhibiting ?-2,3-sialyltransferase activity in cells, and methods for treating a patient having a disease responsive to inhibition of ?-2,3-sialyltransferase activity.
    Type: Application
    Filed: July 3, 2006
    Publication date: May 22, 2008
    Inventors: Wen-Shan Li, Yi-Ching Wang, Hsueh-Fen Juan
  • METHODS OF FEMALE SEXUAL ENHANCEMENT
    Publication number: 20080119445
    Abstract: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and tadalafil prior to sexual activity. The selected drug may be loaded into a starch strip which is then applied to the woman's tongue. Sexual enhancement in women can also be achieved by transdermal or subcutaneous application of the hormone DHEA.
    Type: Application
    Filed: December 17, 2007
    Publication date: May 22, 2008
    Inventor: John R. Woodward
  • NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION
    Publication number: 20080119416
    Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 22, 2008
    Applicant: Umecrine AB
    Inventors: Torbjorn BACKSTROM, Gianna Ragagnin
  • Estradiol derivatives and pharmaceutical compositions using same
    Patent number: 7371741
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: May 13, 2008
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Theresa M. LaVallee, Victor S. Pribluda, Jamshed H. Shah, Anthony M. Treston
  • CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS
    Publication number: 20080103119
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbamates of the formula and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Application
    Filed: July 13, 2007
    Publication date: May 1, 2008
    Applicant: SEPRACOR INC.
    Inventors: Mark G. Currie, Steve Jones, Paul Grover, Chris H. Senanayake, Q. Kevin Fang
  • Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase
    Publication number: 20080081078
    Abstract: Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.
    Type: Application
    Filed: March 30, 2007
    Publication date: April 3, 2008
    Applicant: The Board of Trustees of the University of Illinois
    Inventor: Primal de Lanerolle
  • Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent
    Patent number: 7351699
    Abstract: The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: April 1, 2008
    Assignee: L'Oreal
    Inventors: Olivier De Lacharriere, Stephanie Nouveau
  • Suppression of estrus in mares by a single injection method
    Publication number: 20080051381
    Abstract: The present invention generally relates to methods of suppressing estrus in breeding or competitive animals comprising parenterally administering to breeding animals an estrus suppressing amount of 17-?-Allyl-17-?-hydroxyoestra-4,9,11-trien-3-one. According to the method of the present invention, estrus can be suppressed for any of a variety of periods including 30 days or more. Furthermore, the method of the present invention includes repeated sustained release doses for an indefinite period.
    Type: Application
    Filed: August 22, 2006
    Publication date: February 28, 2008
    Inventor: Patrick J. Burns
  • OCULAR ADMINISTRATION OF TESTOSTERONE
    Publication number: 20080045486
    Abstract: The present invention provides improving health in a woman or man comprising non-orally administering a testosterone-containing moiety to said woman or man by topically applying a liquid composition including said testosterone-containing moiety to the eye of said woman or man in an amount sufficient to provide a therapeutic effect.
    Type: Application
    Filed: August 17, 2006
    Publication date: February 21, 2008
    Inventors: Diane D.S. Tang-Liu, Zhiling Yu, Ronald Bradford
  • Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
    Publication number: 20070280995
    Abstract: Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.
    Type: Application
    Filed: June 1, 2007
    Publication date: December 6, 2007
    Applicant: NOVAGALI PHARMA SA
    Inventors: Laura Rabinovich-Guilatt, Gregory Lambert
  • Fluticasone lotion having improved vasoconstrictor activity
    Patent number: 7300669
    Abstract: A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: November 27, 2007
    Assignee: Altana Inc.
    Inventors: Gordon J. Dow, Keith Arthur Johnson, Frances Furr Kelly, Robert William Lathrop, Rukmini Rajagopalan
  • Combinations for the treatment of immunoinflammatory disorders
    Patent number: 7253155
    Abstract: The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit immunoinflammation.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: August 7, 2007
    Assignee: CombinatoRx, Inc.
    Inventors: Curtis Keith, Alexis Borisy, Grant Zimmerman, Edward Roydon Jost-Price, Palaniyandi Manivasakam, Nicole Hurst, Michael A. Foley
  • Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
    Patent number: 7223387
    Abstract: A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to about 25 weight % propylene glycol and about 10 to about 25 weight percent isopropyl C12–C22 alkanoic ester. The compositions have utility in the treatment or prophylaxis of herpesvirus infections and exhibit superior antiviral and therapeutic efficacy and an improved shelf life.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: May 29, 2007
    Assignee: Medivir AB
    Inventor: Gunilla Lekare
  • Platinum complexes having antitumor activity
    Patent number: 7205287
    Abstract: A platinum complex having antitumor activity in which the metal ligands are dehydrocholic acid and phosphine.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: April 17, 2007
    Assignee: ICE s.r.l.
    Inventors: Enzo Bartoli, Beniamino Palmieri, Alessandro Medici
  • 17?-fluorosteroids, pharmaceutical compositions containing 17?-fluorosteroids and a method of making them
    Patent number: 7199115
    Abstract: New 17?-fluorosteroid compounds of formula (I) are disclosed: wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5?-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: April 3, 2007
    Assignee: Schering AG
    Inventors: Ulrich Bothe, Peter Droescher, Walter Elger, Gudrun Reddersen, Bernd Menzenbach, Hans-Udo Schweikert, Alexander Hillisch, Birgitt Schneider
  • Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
    Patent number: 7199116
    Abstract: Modulating the metabolism of a dieting mammal by administering to the dieting mammal the metabolic modulating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: April 3, 2007
    Assignee: Humanetics Corporation
    Inventor: John Zenk
  • Dry powder for inhalation
    Patent number: 7186401
    Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: March 6, 2007
    Assignee: Jagotec AG
    Inventors: Manfred Keller, Rudi Müller-Walz
  • Pharmaceutical compositions for nasal delivery of oestradiol and norethisterone
    Patent number: 7182960
    Abstract: The present invention relates to a pharmaceutical composition for administration by the nasal route of 17-?-oestradiol and norethisterone.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: February 27, 2007
    Assignee: Les Laboratoires Servier
    Inventors: Gilles Fonknechten, Patrick Wuthrich, Yannis Tsouderos, Claire Varin
  • Stable topical drug delivery compositions
    Patent number: 7182956
    Abstract: A stable composition of a drug comprising a carrier having a phosphatidylcholine component which entraps the drug is applied to the skin for transdermal delivery of the drug.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: February 27, 2007
    Inventors: Nicholas V. Perricone, Chim Potini
  • Method of decreasing atherosclerosis and its complications
    Patent number: 7169768
    Abstract: A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease wherein the method involves administering to a human or an animal an amount of an inhibitor of the release of LHRH or GnRH.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: January 30, 2007
    Inventors: Kenneth M. Weisman, Michael Goldberg
  • GABAmodulating neurosteroids
    Patent number: 7064116
    Abstract: The present invention relates to novel steroid derivatives that ace on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex as well as methods for making the same and their applications to induce anesthesia, in the treatment of stress, anxiety, PMS, PND, and seizures such as those caused by epilepsy, to ameliorate or prevent the attacks of anxiety, muscle tension, and depression common with patients suffering from central nervous system abnormalities. The present invention comprises a compound represented by Formula (I): wherein, R, R1, R2, R3, R4, R5 are defined in the description of the invention. The present invention also includes formulations which consist of one or more of the compounds of Formula (I).
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: June 20, 2006
    Inventors: Theodora Calogeropoulou, Andrew Tsotinis, Charikleia Souli, Alexandros Makriyannis
  • High potency dihydroergotamine compositions
    Patent number: 7060694
    Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: June 13, 2006
    Assignee: Pozen Inc.
    Inventors: John R. Plachetka, Donna Gilbert
  • Use of biogenic estrogen sulfamates for hormone replacement therapy
    Patent number: 7053077
    Abstract: The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: May 30, 2006
    Assignee: Schering AG
    Inventors: Walter Elger, Pekka Lähteenmäki, Matti Lehtinen, Gudrun Reddersen, Holger Zimmermann, Michael Oettel, Sigfrid Schwarz
  • DHEA composition and method
    Patent number: 7045513
    Abstract: Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: May 16, 2006
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jagdish Parasrampuria, Maxine B. Yonker, Kenneth E. Schwartz, Marc J. Gurwith
  • Estradiol conjugates and uses thereof
    Patent number: 7037907
    Abstract: A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 2, 2006
    Assignee: The University of Melbourne
    Inventors: Alastair George Stewart, David James McAllister, Maree Patricia Collis, Alan Duncan Robertson
  • 17?-amino and hydroxylamino-11 ?-arylsteroids and their derivatives having agonist or antagonist hormonal properties
    Patent number: 7018991
    Abstract: The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: March 28, 2006
    Assignee: Research Triangle Institute
    Inventors: C. Edgar Cook, John A. Kepler, Gary S. Bartley, Rupa S. Shetty
  • Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
    Patent number: 7005428
    Abstract: Novel methods for the medical treatment and/or inhibition of the development of hypercholesterolemia in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3?,17?-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: February 28, 2006
    Assignee: Endorecherche, Inc.
    Inventor: Fernand Labrie
  • Prevention of ovarian cancer by administration of progestin products
    Patent number: 6977250
    Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: December 20, 2005
    Assignee: New Life Pharmaceuticals Inc.
    Inventor: Gustavo C. Rodriguez
  • Process for the preparation of a high purity composition comprising (7?, 17?)- 17-hydroxy- 7-methyl- 19-nor-17-pregn-5(10)-en-20-yn-3-one
    Patent number: 6969708
    Abstract: The invention pertains to a process for the preparation of a high purity composition of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5% of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: November 29, 2005
    Assignee: Akzo Nobel N.V.
    Inventors: Peter H. G. M. Kirchholtes, Gerard A. J. M. T. Sas
  • 14 ?, 16, 17-methylene steroids as novel androgens
    Patent number: 6949531
    Abstract: Disclosed are androgenic steroids of the (14?,17?)-17-(hydroxymethyl) type. The invention relates to an improvement thereof, which is based on the presence of a ?-oriented, annellated cyclopropyl group which includes carbon atoms 16 and 17 of the steroid skeleton, i.e. a 16,17?-methylene moiety. These steroids show an unexpectedly high androgenic potency.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: September 27, 2005
    Assignee: Akzo Nobel N.V.
    Inventors: Jaap Van Der Louw, Dirk Leysen, Marcel Evert De Gooijer
  • Use of ?5-androstene-3?-ol-7,17-dione in the treatment of lupus erythematosus
    Patent number: 6924274
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of ?5-androstene-3?-ol-7,17-dione and metabolizable precursors thereof, such as ?5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to ?5-androstene-3?-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: August 2, 2005
    Assignee: Humanetic Corp.
    Inventors: Henry A. Lardy, Charles E. Weeks